RxDoctor Payments Data

Ruksana Jabeen, MD

Hospitalist · Richmond, VANPI 1376653600

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 28 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Johnson & Johnson accounts for 79.0% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2022 at $337 and has fallen 89.3% since, to $36 in 2025. Among hospitalist clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$595in general payments, 2019–2025

Across 28 payments — averaging $21.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$470
  • Pfizer$52
  • AstraZeneca$37
  • Stryker$36

What the payments were for

  • Food & beverage$595100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson22$470
Pfizer3$52
AstraZeneca2$37
Stryker1$36

How this compares

$595 in reported general payments places this provider in the 90th percentile of 539 hospitalist providers in Virginia.

See all hospitalist providers in Virginia

Medicare billing

Part B allowed, 2024
$151,656
Medicare patients
388
Services billed
1,629

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban19$11,087
Prednisone41$405
Cefdinir39$282
Dexamethasone26$275
Pantoprazole Sodium33$229
Metoprolol Succinate20$223
Trazodone Hcl19$220
Amlodipine Besylate36$172
Doxycycline Hyclate15$141
Gabapentin22$139
Losartan Potassium23$126
Quetiapine Fumarate14$124
Methocarbamol27$101
Oxycodone Hcl18$98
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav22$97

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$52$11,08719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 539 hospitalist providers in Virginia.

Other hospitalist in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →